NCT02585440

A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects

A Phase 1, Randomized, Partial-Blind, Placebo-controlled, Sequential Dose Group, Ascending, Multiple Dose Study of the Safety, Tolerability and Pharmacokinetics, With Food Effect, of CMX157 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: ContraVir Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a phase 1 study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels.

Detailed description

This is a phase 1 study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels, in a fasted state and a fed state.

Conditions

• Infectious Disease

Interventions

Type	Name	Description
DRUG	CMX157	Oral tablet
DRUG	placebo	Oral tablet

Timeline

• Start date: 2016-04-01
• Primary completion: 2016-08-01
• Completion: 2016-09-01
• First posted: 2015-10-23
• Last updated: 2017-02-02

Locations

1 site across 1 country: Thailand